Skip to content
value.today

BIND Biosciences Inc

Total raised
$47 M
3 rounds on record
Latest round
$9 M
Jan 2013
First round on record
Jun 2010
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of BIND Biosciences Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2013$9 MNo. 3$2 to $10 million

BIND Biosciences Inc: Raise no. 3, Jan 2013

Investors in this round

20 investors had bought by the notice of Feb 8, 2013: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for BIND Biosciences Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$9 M of $20 M offered; $12 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew S. Hirsch · Executive Officer
  • Daniel Koerwer · Executive Officer
  • James Wright · Executive Officer
  • Jeffrey Hrkach · Executive Officer
  • Scott Minick · Executive Officer, Director
  • Stephen Zale · Executive Officer
  • Amir H. Nashat · Director
  • Daniel S. Lynch · Director
  • Noubar Afeyan · Director
  • Omid C. Farokhzad · Director
  • Peter Barton Hutt · Director
  • Robert Barton Langer, Jr. · Director
  • Yuriy H. Udaltsov · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Amounts sold includes amounts received from foreign investors. Amount remaining to be sold may be sold at a second tranche closing.”

Signed by Andrew Hirsch, Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 8, 2013. Read the notice at the SEC.

equitySEC
Nov 2011$26 MNo. 2$10 to $50 million

BIND Biosciences Inc: Raise no. 2, Nov 2011

Investors in this round

21 investors had bought by the notice of Nov 22, 2011: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for BIND Biosciences Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$26 M of $47 M offered; $22 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrea Franz · Executive Officer
  • Daniel Koerwer · Executive Officer
  • Edward Schnipper · Executive Officer
  • James Wright · Executive Officer
  • Jeffrey Hrkach · Executive Officer
  • Paul Burgess · Executive Officer
  • Scott Minick · Executive Officer, Director
  • Stephen Zale · Executive Officer
  • Amir H. Nashat · Director
  • Noubar Afeyan · Director
  • Omid C. Farokhzad · Director
  • Peter Barton Hutt · Director
  • Robert Barton Langer, Jr. · Director
  • Yuriy H. Udaltsov · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes amounts received upon conversion of Promissory Notes for which a Form D was previously filed. Also includes amounts received from foreign investors.”

Signed by Andrea Franz, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 22, 2011. Read the notice at the SEC.

equitySEC
Jun 2010$12 MNo. 1$10 to $50 million

BIND Biosciences Inc: Raise no. 1, Jun 2010

Investors in this round

18 investors had bought by the notice of Jun 29, 2010: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for BIND Biosciences Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrea Franz · Executive Officer
  • Ed Schnipper · Executive Officer
  • Jim Wright · Executive Officer
  • Scott Minick · Executive Officer, Director
  • Amir S Nashat · Director
  • Noubar Afeyan · Director
  • Omid Farokhzad · Director
  • Peter Barton Hutt · Director
  • Robert S Langer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Not including salaries and bonuses paid to executive officers in the ordinary course of business.”

Signed by Andrea Franz, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 29, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • BIND Biosciences Inc chose not to state its revenue in its newest notice of a funding round (Feb 2013).

    SEC Form D · Feb 2013

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Feb 2013

That is all the official record says: BIND Biosciences Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

8 named in official filings. Open an investor to see everything it has backed.

Investors in BIND Biosciences Inc
InvestorKindAmountRoundRoleSource
Flagship Ventures Fund 2004 L.P.Venture capitalnot statednot statedHeld Series A, B, C, C-1 and D preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Flagship Ventures General Partner LLCVenture capitalnot statednot statedHeld Series A, B, C, C-1 and D preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Polaris Venture Management Co. V, L.L.C.Venture capitalnot statednot statedHeld Series A, B, C, C-1 and D preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Polaris Venture Partners Entrepreneurs' Fund V, L.P.Venture capitalnot statednot statedHeld Series A, B, C, C-1 and D preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Polaris Venture Partners Founders' Fund V, L.P.Venture capitalnot statednot statedHeld Series A, B, C, C-1 and D preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Polaris Venture Partners Special Founders' Fund V, L.P.Venture capitalnot statednot statedHeld Series A, B, C, C-1 and D preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Polaris Venture Partners V, L.P.Venture capitalnot statednot statedHeld Series A, B, C, C-1 and D preferred stock, 10% owner (Form 3, 2013)SEC Form 3
RusnanoPersonnot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2013)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 21 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by BIND Biosciences Inc
NameRoleNamed in
Andrew S. HirschExecutive officerFeb 2013
Daniel KoerwerExecutive officerFeb 2013
James WrightExecutive officerFeb 2013
Jeffrey HrkachExecutive officerFeb 2013
Scott MinickExecutive officerFeb 2013
Stephen ZaleExecutive officerFeb 2013
Andrea FranzExecutive officerNov 2011
Edward SchnipperExecutive officerNov 2011
Paul BurgessExecutive officerNov 2011
Ed SchnipperExecutive officerJun 2010
Jim WrightExecutive officerJun 2010
Amir H. NashatDirectorFeb 2013
Daniel S. LynchDirectorFeb 2013
Noubar AfeyanDirectorFeb 2013
Omid C. FarokhzadDirectorFeb 2013
Peter Barton HuttDirectorFeb 2013
Robert Barton Langer, Jr.DirectorFeb 2013
Scott MinickDirectorFeb 2013
Yuriy H. UdaltsovDirectorFeb 2013
Amir S NashatDirectorJun 2010
Omid FarokhzadDirectorJun 2010
Robert S LangerDirectorJun 2010